| Name of the Instrument/Tool | Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) |
| First Description |
Albrecht J, Taylor L, Berlin JA,et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889-94 |
| Year | 2005 |
| Domains | |
| Concept of constructs | Skin, Disease activity |
| Population/Disease | Disease specific |
| Originally developed for | Systemic Lupus Erythematosus (SLE) |
| Other rheumatic diseases where can be applied (only if validated) |
--- |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English |
| Available in Language | --- |
| REFERENCE IDENTIFICATION | |
| Author/s | Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP |
| Title | The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus |
| Journal | J Invest Dermatol |
| Year | 2005 |
| Vol | 125 |
| Num | 5 |
| Pages | 889-94 |
| Country | USA |
| Language | English |
| Other references of interest | |
| Link | https://pubmed.ncbi.nlm.nih.gov/23107310/ |
| Brief Description |
Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures |
| Link | https://pubmed.ncbi.nlm.nih.gov/21339447/ |
| Brief Description |
Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus |
| Link | https://pubmed.ncbi.nlm.nih.gov/33091256/ |
| Brief Description |
Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage |
| Instrument/Tool Translations References | |
| No other References. | |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Dr. Victoria Werth |
| werth@pennmedicine.upenn.edu | |
| Address | Division of Dermatology, Philadelphia V.A. Hospital |
| Website | https://www.pennmedicine.org/providers/profile/victoria-werth |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Composite Index |
| Brief Description |
The CLASI is an organ‐specific outcome measure used to assess and grade cutaneous manifestations in both SLE and cutaneous lupus erythematosus (CLE). The CLASI has two scores. The activity (A) score describes activity of the disease, whereas the damage score (D) describes damage caused by the disease. It is designed as a table in which rows denote anatomical areas and columns include scores for major clinical symptoms. |
| Number of Items | Items for activity include erythema, scale/hypertrophy, mucous membrane involvement, acute hair loss, and no scarring alopecia. |
| Range | 0-70 |
| Responses options/scale |
Yes Response options are recorded as dichotomous (presence/absence of symptoms) and vary from 0 to 6, depending on the extent of severity. |
| Developed for | Clinical practice, Research |
| PRACTICAL APPLICATION | |
| Method of administration | Physician |
| Recommendations to score |
Scores are summated in each of the two domains of activity and damage. To increase the score's responsiveness, more weight has been given to photosensitive areas, such as the face, neck, and hands. Patients are asked whether depigmentation has occurred in CLE lesions and has remained visible for more than 12 months, which is taken to be permanent. If so, the depigmentation score is doubled. |
| Score Interpretation | Higher scores indicate higher disease severity |
| Cut-off points | 0 to 9: Mild, 10 to 20: Moderate, and 21 to 70: Severe |
| Cut-off points applied to | --- |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | 2-10 minutes |
| Scoring time by the assessor | <10 minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments | --- |